By reNEW – Novo Nordisk Foundation Center for Stem Cell Medicine
A patient suffering from moderate Parkinson’s disease (PD) was first out on Feb 13, 2023, to receive a transplant with the human stem cell-derived nerve cell product STEM-PD at Skåne University Hospital in southern Sweden. This is the result of a decade long research effort in which reNEW Copenhagen’s Associate Professor Agnete Kirkeby led the pre-clinical development of the cell product.
The STEM-PD product is an embryonic stem cell-derived product consisting of human dopamine neuron progenitor cells for transplantation to the brains of Parkinson’s disease patients. The hope is that these stem cells will mature into new and healthy dopamine-producing nerve cells within the brains of the trial participants and thereby alleviate the patients’ parkinsonian symptoms.
